Amgen (AMGN) EBIT Margin (2009 - 2026)
Amgen (AMGN) posted EBIT Margin of 34.95% for Q2 2026, up 12.98% on a QoQ basis from 30.94% in Q1 2026, and up 602.0% year-over-year from 4.98% in Q2 2025.
Powered by 
Analysis
Amgen (AMGN) EBIT Margin (2009 - 2026) Analysis & Trends
Amgen has reported EBIT Margin for 18 years, with the latest figure at 34.95% in Q2 2026.
- On a quarterly basis, EBIT Margin rose 602.0% year-over-year to 34.95% in Q2 2026; TTM through Jun 2026 was 29.99%, a 653.0% increase from a year earlier, with the FY2025 full-year figure at 24.71%, up 299.0% from the prior year.
- EBIT Margin was 34.95% for Q2 2026 at Amgen, up from 30.94% in the prior quarter.
- The five-year high for EBIT Margin was 485.84% in Q4 2022, with the low at 13.31% in Q1 2024.
- Average EBIT Margin over 5 years is 53.47%, with a median of 29.11% recorded in 2023.
- The sharpest annual moves came in 2022 and 2023: EBIT Margin soared 45218 bps in 2022, then tumbled 47033 bps in 2023.
- Over 5 years, EBIT Margin stood at 485.84% in 2022, then tumbled by 97 bps to 15.51% in 2023, then soared by 64 bps to 25.43% in 2024, then increased by 8 bps to 27.57% in 2025, then grew by 27 bps to 34.95% in 2026.
- The last three EBIT Margin figures came in at 34.95% (Q2 2026), 30.94% (Q1 2026), and 27.57% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -23.56% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.36% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -897.82% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34.95% |
| Mar 31, 2026 | 30.94% |
| Dec 31, 2025 | 27.57% |
| Sep 30, 2025 | 26.43% |
| Jun 30, 2025 | 28.94% |
| Mar 31, 2025 | 14.46% |
| Dec 31, 2024 | 25.43% |
| Sep 30, 2024 | 24.07% |
| Jun 30, 2024 | 22.76% |
| Mar 31, 2024 | 13.31% |
| Dec 31, 2023 | 15.51% |
| Sep 30, 2023 | 29.28% |
| Jun 30, 2023 | 38.42% |
| Mar 31, 2023 | 31.47% |
| Dec 31, 2022 | 485.84% |
| Sep 30, 2022 | 39.99% |
| Jun 30, 2022 | 33.00% |
| Mar 31, 2022 | 40.08% |
| Dec 31, 2021 | 33.65% |
| Sep 30, 2021 | 35.46% |